Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension

Aprocitentan (a dual endothelin receptor antagonist) for Treatment-Resistant Hypertension

Journal of Cardiovascular Pharmacology ◽

10.1097/fjc.0000000000001023 ◽

2021 ◽

Vol Publish Ahead of Print ◽

Author(s):

Emily K. McCoy ◽

Katelin M. Lisenby

Keyword(s):

Receptor Antagonist ◽

Resistant Hypertension ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Treatment Resistant

Download Full-text

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial

Yearbook of Cardiology ◽

10.1016/s0145-4145(10)79836-1 ◽

2010 ◽

Vol 2010 ◽

pp. 102-104

Author(s):

W.J. Elliott

Keyword(s):

Blood Pressure ◽

Receptor Antagonist ◽

Resistant Hypertension ◽

Controlled Trial ◽

Reduce Blood Pressure ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Treatment Resistant ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial

The Lancet ◽

10.1016/s0140-6736(09)61500-2 ◽

2009 ◽

Vol 374 (9699) ◽

pp. 1423-1431 ◽

Cited By ~ 200

Author(s):

Michael A Weber ◽

Henry Black ◽

George Bakris ◽

Henry Krum ◽

Stuart Linas ◽

...

Keyword(s):

Blood Pressure ◽

Receptor Antagonist ◽

Resistant Hypertension ◽

Controlled Trial ◽

Reduce Blood Pressure ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Treatment Resistant ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1184971.647074 ◽

2009 ◽

Author(s):

Mahboob Rahman

Keyword(s):

Blood Pressure ◽

Receptor Antagonist ◽

Resistant Hypertension ◽

Controlled Trial ◽

Reduce Blood Pressure ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Treatment Resistant ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1184971.746081 ◽

2009 ◽

Author(s):

David Pollock

Keyword(s):

Blood Pressure ◽

Receptor Antagonist ◽

Resistant Hypertension ◽

Controlled Trial ◽

Reduce Blood Pressure ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Treatment Resistant ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Endothelin Receptor Antagonist

10.32388/54vclc ◽

2020 ◽

Author(s):

Keyword(s):

Receptor Antagonist ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor

Download Full-text

Faculty Opinions recommendation of Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13198963.14726480 ◽

2011 ◽

Author(s):

Luciana Mascia ◽

Ilaria Mastromauro

Keyword(s):

Subarachnoid Haemorrhage ◽

Receptor Antagonist ◽

Endothelin Receptor Antagonist ◽

Aneurysmal Subarachnoid Haemorrhage ◽

Endothelin Receptor ◽

Surgical Clipping ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8282963.8711064 ◽

2011 ◽

Author(s):

David Welsh

Keyword(s):

Receptor Antagonist ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Tissue Targeting ◽

Orally Active

Download Full-text

Effect of Chronic Treatment of Adult Spontaneously Hypertensive Rats With an Endothelin Receptor Antagonist

Hypertension ◽

10.1161/01.hyp.25.4.495 ◽

1995 ◽

Vol 25 (4) ◽

pp. 495-500 ◽

Cited By ~ 74

Author(s):

Jin-S. Li ◽

Ernesto L. Schiffrin

Keyword(s):

Receptor Antagonist ◽

Spontaneously Hypertensive Rats ◽

Chronic Treatment ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Hypertensive Rats ◽

Spontaneously Hypertensive

Download Full-text

ChemInform Abstract: Endothelin Receptor Antagonist Triterpenoid, Myriceric Acid A, Isolated from Myrica cerifera, and Structure Activity Relationships of Its Derivatives.

ChemInform ◽

10.1002/chin.199633208 ◽

2010 ◽

Vol 27 (33) ◽

pp. no-no

Author(s):

K. SAKURAWI ◽

F. YASUDA ◽

T. TOZYO ◽

M. NAKAMURA ◽

T. SATO ◽

...

Keyword(s):

Receptor Antagonist ◽

Endothelin Receptor Antagonist ◽

Endothelin Receptor ◽

Myrica Cerifera ◽

Structure Activity Relationships ◽

Structure Activity ◽

Myriceric Acid A

Download Full-text